Bio China 2012

Follow Us

Facebook Twitter YouTube LinkedIn | BIO Business Links



Chinese Pharmaceutical Sales See Continued Growth

China is positioned to overtake Japan as the world’s second largest pharmaceutical market by 2015. According to GBI, a leader in China pharmaceutical data intelligence, last year’s pharmaceutical sales in China grew by 20% or more in almost all major therapeutic areas. A combination of factors are driving this growth, such as the expansion of the middle class, increased access to western medicines, the significant expansion of China’s essential drug list (EDL), and the growth of China’s elderly population which is on track to reach 200 million people in 2013.

The highest growth in 2012 was found in the central nervous system (CNS) pharmaceuticals market with a 42% increase to USD $4.1 Billion in sales. Similarly, pharmaceuticals designed for blood ailments, GI & metabolism diseases and cardiovascular disease each enjoyed robust growth of 28% and total sales of $20.9 Billion. At the low end, anti-infectives saw relatively modest growth of 3%, but maintained the largest market share with USD $12.2 Billion in sales.

As China continues on the path of strong economic development and growth, the healthcare needs of its citizens will continue to evolve. Opportunities for Western companies to gain a presence in the burgeoning Chinese pharmaceutical market are plentiful and opportunities continue to grow.

Delve deeper into China’s budding pharmaceutical market by attending the panel on the state of capital markets in the U.S. and China at this year’s BIO Convention in China, taking place November 11-13th in Beijing. To view the preliminary brochure, please click here.  

Marketplace Intelligence

As an attendee of the 2013 BIO Convention in China, BIO is pleased to offer your organization a 90 day trial of GBI’s ground-breaking intelligence systems. For $10,000 receive SOURCE, GBI's gold standard news and intelligence resource tracking China’s pharmaceutical and biotechnology industry or for $8,000 access METRIX, comprising unparalleled R&D intelligence. These special offer prices provide your team with access to the most comprehensive information on China’s pharmaceutical and R&D landscapes; drugs, pipelines, companies, prices, tenders, news and policies; KOLs; academic information, patent filings and more — an essential resource for decision making. For more information, please visit

The 3rd annual BIO Convention in China will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech and rapidly expanding pharmaceutical sectors. For more information or to register, visit

Add to your contacts to ensure email delivery.
Not displaying correctly? View this email in a browser.
If you received this message from a colleague, or would like to
receive information on our full spectrum of events, please click here.